FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	L OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person*  Kouchakji Elias  (Last) (First) (Middle)  C/O FIBROGEN, INC.					2. Is FI	2. Issuer Name and Ticker or Trading Symbol FIBROGEN INC [ FGEN ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Tofficer (give title Other (specify below)  3. Date of Earliest Transaction (Month/Day/Year)  02/24/2021  5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Officer (give title Other (specify below)  SVP, Clinical Dev, Drug Safety									vner specify				
409 ILLINOIS ST.				4. li	If Amendment, Date of Original Filed (Month/Day/Year)     6. Individual or Joint/Group Filing (Check Applicable)								plicable						
(Street) SAN FRANCI	ISCO C.	A	94158		-				-			,		Line)		led by More		orting Perso	- 1
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		3. Transaction Code (Instr. 8) 1			A) or , 4 and		es For ally (D) Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock 02/24/				4/202	/2021 A		20,800	0 <sup>(1)</sup> A \$		\$0.00	152,567			D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)  2. Conversi or Exerci Price of Price of Derivative Security			3A. Deemed Execution Dat if any (Month/Day/Ye	Date,	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	nount imber ares					
Stock Option (Right to Buy)	\$53.01	02/24/2021			A		39,900		(2)	(	02/24/2031	Common Stock	39	9,900	\$0.00	39,900	)	D	

## **Explanation of Responses:**

- 1. Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three
- 2. Twenty-five percent of the shares subject to the option vests on March 1, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years

## Remarks:

/s/ Dorothy Pacini, Attorney-in-02/26/2021

fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.